Athira Pharma Reports First Quarter 2023 Financial Results and Recent Pipeline and Business Updates

Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer’s disease to focus on 40 mg dose Open label extension trial to be extended, providing up to 36 months of long-term... | May 11, 2023

Related Keywords

Washington ,United States ,Seattle ,American ,Julie Rathbun ,Mark Litton ,Athira Pharma ,International Conference On Alzheimer ,Facebook ,American Association Of Neurology ,Nasdaq ,Securities Exchange ,Athira Pharma Inc ,Instagram ,Linkedin ,Development Rd Expenses ,Exchange Commission ,National Institutes Of Health ,Twitter ,Clinical Development Pipeline Programs ,Drug Administration ,Chief Executive Officer ,Mini Mental State Exam ,Label Extension ,National Institute ,National Institutes ,American Association ,Related Neurological Disorders ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Consolidated Statements ,Nc Stock Exchange ,News ,Information ,Press Release ,Hase ,Trial ,F ,Fosgonimeton ,Or ,Disease ,O ,Focus ,N , 0 ,G ,Nose ,Pen ,Label ,Extension ,The ,Roviding ,P ,6 ,Months ,F Atha Us04746l1044 ,